Adagene announced the completion of patient enrollment for its Phase 2 trial of muzastotug in combination with Merck's KEYTRUDA for late-line MSS CRC. This milestone indicates progress in the clinical development of a potential new therapy for a challenging cancer, aiming to improve upon existing anti-CTLA-4 treatments.
Adagene Inc. has completed patient enrollment for its Phase 2 trial of muzastotug (ADG126) in combination with Merck's KEYTRUDA. This is a significant operational milestone in drug development, indicating that the trial is progressing as planned and moving closer to data readout. The trial targets late-line microsatellite stable colorectal cancer (MSS CRC) without liver metastases, a patient population with high unmet medical needs. For Adagene, this completion de-risks the timeline for the trial and could lead to future positive data readouts, which would be a long-term positive catalyst. For Merck, it's a relatively minor event as KEYTRUDA is already a blockbuster, but a successful combination could expand its market. Traders should note that while enrollment completion is positive, the actual efficacy data is still pending, representing the key short-term risk and long-term opportunity for Adagene.